You are here

Approvals, Launches, and New Indications

New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
More Than 32% of Patients Responded in Trial
Evenity Increases New Bone Formation, Lowers Vertebral Fracture Potential
Dovato Achieved Non-inferior Efficacy Compared to Traditional Regimen; No Cases of Resistance
LAMA/LABA Population Expected to Grow Rapidly in Coming Years
Approximately 250,000 People in the U.S. Live with PI
Majority of Trial Patients Achieved Normal Testoserone Levels
Trial Showed Mayzent Reduced Disability Progression, Relapses 
Patients With Implant Saw Improved Walking Distance
First and Only Treatment Reduces Depressive Symptoms Within Days
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
FDA Prioritizing Review of ARB Applications to Help Mitigate Drug Shortage
For Locally Advanced or Metastatic Triple-Negative Type Only
Subcutaneous Extended-Release Injectable With Risperidone Now Available in the U.S.
Treatment Options Are Limited After Failure of First- and Second-line Therapies
Minimally Invasive Procedure Uses Radio Waves to Thwart Pain
Disease Occurs in 1 in 5,000 Male Births in the U.S.
Liver Fluke Infestation Affects Almost 2.5 Million People Globally
Trial Demonstrated Significantly Improved Survival Rates
New Chemotherapy-Free Option for Treating CLL and SLL
Sole FDA-Approved Test for Sexually Transmitted Infection
New Design Offers More Reliable SQ Delivery of Diabetes Meds  
New Influenza Vaccine Option Could Streamline Immunization Efforts
Herceptin Biosimilar Indicated for HER2-Overexpressing Breast Cancer, Metastatic Breast Cancer, and Metastatic Gastric Cancer
Adjunctive Therapy is First Generic Version of Sabril for Focal Seizures
First and Only Second-Generation TKI for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia